IPCA Laboratories

IPCA Laboratories Debt

The Debt of IPCA Laboratories (IPCALAB.NS) as of Oct 27, 2026 is 1.09 B INR. In the previous year, Debt was 10.89 B INR — a change of -89.98% (lower).

Debt

1.09 BINR

YoY

-89.98%

Last updated:

In 2026, IPCA Laboratories's total debt was 1.09 B INR, a -89.98% change from the 10.89 B INR total debt recorded in the previous year.

The IPCA Laboratories Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
3.51 B INR
Jan 1, 2020
4.27 B INR
Jan 1, 2021
1.94 B INR
Jan 1, 2022
7.74 B INR
Jan 1, 2023
13.31 B INR
Jan 1, 2024
11.80 B INR
Jan 1, 2025
10.89 B INR
Jan 1, 2026
1.09 B INR
The IPCA Laboratories Debt history
YEARDebtYoY
1.09 BINR-89.98%
10.89 BINR-7.65%
11.80 BINR-11.36%
13.31 BINR+71.81%
7.74 BINR+299.24%
1.94 BINR-54.56%
4.27 BINR+21.79%
3.51 BINR-25.90%
4.73 BINR-10.58%
5.29 BINR-20.93%
6.69 BINR-53.48%
14.38 BINR+60.41%
8.97 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Debt Details

Understanding IPCA Laboratories's Debt Structure

IPCA Laboratories's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing IPCA Laboratories's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to IPCA Laboratories’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in IPCA Laboratories’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about IPCA Laboratories stock

Debt of IPCA Laboratories is 1.09 B INR in 2026.

Debt of IPCA Laboratories changed from 10.89 B INR to 1.09 B INR, representing a -89.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Debt's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's IPCA Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — IPCA Laboratories

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — IPCA Laboratories